Joanna D. Sikkema University of Miami School of Nursing None AstraZeneca None None None None 4.4.1.1 Craig R. Smith, Jr Columbia University Chairman, Department of Surgery None None None None None None None Sidney C. Smith, Jr Center for Cardiovascular Science and Medicine Professor of Medicine; Director Eli Lilly (Expired July Sanofi-aventis (Expired Sept. 2009) AstraZeneca (Expired Bayer (Expired Oct. Fornier (Expired May Sanofi-aventis (Expired Nov. 2009) None GlaxoSmithKline (DSMB) (Expired None None 4.4.2.1 (Continued) Appendix 1. Continued Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* John A. Spertus MidAmerica Heart Institute of St. Luke s Hospital Director, Outcomes Research; University of Missouri Kansas City Gilead None None BMS/sanofi- aventis Cordis Eli Lilly Johnson & Johnson Roche Diagnostics None None 4.4.1.1 Sankey V. Williams Hospital of the University of Pennsylvania Solomon Katz Professor of General Medicine, Division of General Internal Medicine None None Johnson & Johnson Merck None None None 4.4.1.1 This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership of $$10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. 